FGFR2 and renal pelvis/ureter urothelial carcinoma: Currently, activating mutations in FGFR2 and FGFR3 genes were actionable with highest level of evidence in UC, especially for UTUC, as erdafitinib (a FGFR inhibitor) was proved to have a 40% objective response rate in previously treated locally advanced and unresectable or metastatic UC with FGFR2/3 alterations [11].